Evidence map›Paper›PMID 35902696›Full record

ArticleEuropean journal of human genetics : EJHG2022

Variable expressivity in a four-generation ACDMPV family with a non-coding hypermorphic SNV in trans to the frameshifting FOXF1 variant.

Esra Yıldız Bölükbaşı, Justyna A Karolak, Przemyslaw Szafranski, Tomasz Gambin, Admire Matsika, Sam McManus, Hamish S Scott, Peer Arts, Thuong Ha, Christopher P Barnett and 2 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in European journal of human genetics : EJHG, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Happy 30th birthday to the European Journal of Human Genetics!European journal of human genetics : EJHG · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Esra Yıldız BölükbaşıDepartment of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Justyna A KarolakChair and Department of Genetics and Pharmaceutical Microbiology, Poznan University of Medical Sciences, Poznan, Poland.
Przemyslaw SzafranskiDepartment of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Tomasz GambinInstitute of Computer Science, Warsaw University of Technology, Warsaw, Poland.
Admire MatsikaMater Pathology, Mater Hospital Brisbane, South Brisbane, QLD, Australia.
Sam McManusMater Pathology, Mater Hospital Brisbane, South Brisbane, QLD, Australia.
Hamish S ScottDepartment of Genetics and Molecular Pathology, Centre for Cancer Biology, An alliance between SA Pathology and the University of South Australia, Adelaide, SA, Australia.ORCID 0000-0002-5813-631X
Peer ArtsDepartment of Genetics and Molecular Pathology, Centre for Cancer Biology, An alliance between SA Pathology and the University of South Australia, Adelaide, SA, Australia.ORCID 0000-0002-6742-6239
Thuong HaDepartment of Genetics and Molecular Pathology, Centre for Cancer Biology, An alliance between SA Pathology and the University of South Australia, Adelaide, SA, Australia.
Christopher P BarnettAdelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
Jonathan Rodgers *Genetic Health Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Paweł Stankiewicz *Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX, USA. pawels@bcm.edu.ORCID 0000-0002-6456-7490
Baylor College of Medicine · USSouth Australia Pathology · AUMater Adult Hospital · AUPoznan University of Medical Sciences · PLThe University of Queensland · AUWarsaw University of Technology · PLWomen's and Children's Hospital · AU

Funding

Epigenomic dysfunction at 16q24.1 vascular defects and perinatal consequencesR01HL137203 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI STANKIEWICZ, PAWEL · 2017 to 2020
$2.0M
NHLBI NIH HHS R01 HL137203
6 · The paper itself

Abstract

Heterozygous single nucleotide variants (SNVs) or copy-number variant deletions involving FOXF1 or its distant lung-specific enhancer on chromosome 16q24.1 have been identified in 80-90% of patients with Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV), a lethal neonatal lung developmental disorder. We describe a four-generation family with a deceased ACDMPV neonate, her sibling from the electively terminated pregnancy, healthy mother with a history of pulmonary arterial hypertension (PAH), an unaffected aunt, an aunt deceased due to findings consistent with ACDMPV, and a reportedly unaffected grandmother, all with the frameshifting variant c.881_902dup (p.Gly302Profs*46) in FOXF1, and a deceased great-grandmother with a history of PAH. Genome sequencing analyses in the proband's unaffected mother revealed a non-coding putative regulatory SNV rs560517434-A within the lung-specific distant FOXF1 enhancer in trans to the FOXF1 frameshift mutation. Functional testing of this variant using an in vitro luciferase reporter assay showed that it increased FOXF1 promoter activity 10-fold. Our studies further demonstrate that non-coding SNVs in the FOXF1 enhancer region can rescue the lethal ACDMPV phenotype and support the compound inheritance gene dosage model.

Indexed as

Forkhead Transcription FactorsPersistent Fetal Circulation SyndromeFemaleFrameshift MutationHumansInfant, NewbornNucleotidesPulmonary AlveoliSequence DeletionForkhead Transcription FactorsFOXF1 protein, humanNucleotides

Identifiers

PMID35902696
PMCPMC9554184
OpenAlexW4288080525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.